PDS Biotech to Host Key Opinion Leader Event on PDS0301 for the Treatment of Advanced Colorectal Cancer with Liver Metastases
Key Highlights
- ➤PDS Biotech to host October 15 KOL event on PDS0301 colorectal cancer trials
- ➤PDS0301 Phase 2 discussion will focus on metastatic colorectal cancer liver metastases
- ➤Trial covers second- and third-line unresectable MSS or pMMR colorectal liver metastases
- ➤MSS patients represent most mCRC, where immunotherapy has mostly been ineffective
Expert Statements
Jonathan M. Hernandez, M.D., Investigator, Surgical Oncology Program, NCI/CCR
“No direct quote provided in the article.”
PRINCETON, N.J., Oct. 06, 2026 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today announced that the Company will host a virtual key opinion leader (KOL) event featuring Jonathan M. Hernandez, M.D, an Investigator with Surgical Oncology Program at the National Cancer Institute’s Center for Cancer Research. Dr. Hernandez will join company management to discuss clinical outcomes from the PDS0301 Phase 2 trials for the treatment of advanced liver-associated cancers, with a focus on the metastatic colorectal cancer (mCRC) cohort. The event will provide an overview of the PDS0301 trial in patients with second and third line unresectable microsatellite stable (MSS) or mismatch repair-proficient (pMMR) colorectal liver metastases. These MSS patients constitute the majority of mCRC, a population in which immunotherapy has been mostly ineffective.
Get started
Create a free account to read the full story.